{
    "symbol": "CAH",
    "quarter": 1,
    "year": 2022,
    "date": "2021-11-09 13:25:10",
    "content": " This change is driven by the significant increases in supply chain costs inflation that I previously discussed, which is expected to result in an incremental net headwind of approximately $100 to $125 million on the year. Given the anticipated timing of realizing these cost increases and our mitigating actions, as well as the timing of selling higher cost PPE, we expect a sequential decline in medical segment  Stepping back, the only large operational item that we see meaningfully different today compared to our original fiscal '22 guidance is the incremental impact of elevated supply chain costs  medical. And so our goal of low single-digit to mid-single-digit growth in Pharma is really focused on strengthening that  balance, getting that right mix of generics, making sure we're managing the balancing through of our margin initiatives and all that as well as then driving our growth businesses, specialty nuclear in out comes, and we gave some color on those. With an additional $3 billion share repurchase authorization and our commitment to our dividend, we are positioned to return capital to shareholders while prioritizing investment in our growth businesses, simplifying our operating model, and strengthening our core businesses."
}